Medkart在印度扩大了人们获得负担得起的心脏药物的机会,将非专利药物的成本削减到90%。 Medkart expands access to affordable heart meds in India, cutting costs up to 90% on generics.

在世界心脏日,古吉拉特最大的非专利第一药店连锁店梅德卡特(Medkart)正在印度各地扩大提供负担得起的心脏病药物,而心脏病是印度的主要死因。 On World Heart Day, Medkart, Gujarat’s largest generic-first pharmacy chain, is expanding access to affordable heart medications across India, where heart disease is the leading cause of death. 通过其Medkart保证计划,该公司提供符合严格规定的高质量仿制药,使患者能够通过其在线平台和应用程序在重复处方上节省高达90%的费用,平均为73%. Through its Medkart Assured program, the company offers high-quality generics compliant with strict regulations, enabling patients to save up to 90% on repeat prescriptions—averaging 73%—via its online platform and app. 该倡议支持坚持治疗、预防和减少并发症,使基本心脏药物更容易获得,同时通过教育和药剂师支持促进对非专利药物的信任。 The initiative supports treatment adherence, prevention, and reduced complications by making essential cardiac drugs more accessible, while also promoting trust in generics through education and pharmacist support.